X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs DR. REDDYS LAB - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD DR. REDDYS LAB BIOCON LTD/
DR. REDDYS LAB
 
P/E (TTM) x 50.6 27.6 183.4% View Chart
P/BV x 7.4 3.4 216.8% View Chart
Dividend Yield % 0.2 0.8 20.3%  

Financials

 BIOCON LTD   DR. REDDYS LAB
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
DR. REDDYS LAB
Mar-18
BIOCON LTD/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,1882,788 42.6%   
Low Rs3051,902 16.0%   
Sales per share (Unadj.) Rs68.7860.8 8.0%  
Earnings per share (Unadj.) Rs7.657.1 13.2%  
Cash flow per share (Unadj.) Rs14.0122.0 11.5%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %0.10.9 15.7%  
Book value per share (Unadj.) Rs86.3757.7 11.4%  
Shares outstanding (eoy) m600.00165.91 361.6%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x10.92.7 398.7%   
Avg P/E ratio x98.941.1 240.6%  
P/CF ratio (eoy) x53.419.2 278.0%  
Price / Book Value ratio x8.63.1 279.4%  
Dividend payout %13.235.0 37.8%   
Avg Mkt Cap Rs m447,900389,034 115.1%   
No. of employees `0006.123.5 26.1%   
Total wages/salary Rs m9,31132,149 29.0%   
Avg. sales/employee Rs Th6,705.86,070.8 110.5%   
Avg. wages/employee Rs Th1,514.21,366.6 110.8%   
Avg. net profit/employee Rs Th736.9402.5 183.1%   
INCOME DATA
Net Sales Rs m41,234142,810 28.9%  
Other income Rs m2,0621,552 132.9%   
Total revenues Rs m43,296144,362 30.0%   
Gross profit Rs m8,29123,512 35.3%  
Depreciation Rs m3,85110,772 35.8%   
Interest Rs m615788 78.0%   
Profit before tax Rs m5,88713,504 43.6%   
Minority Interest Rs m2130-   
Prior Period Items Rs m0344 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5694,380 35.8%   
Profit after tax Rs m4,5319,468 47.9%  
Gross profit margin %20.116.5 122.1%  
Effective tax rate %26.732.4 82.2%   
Net profit margin %11.06.6 165.7%  
BALANCE SHEET DATA
Current assets Rs m41,486104,984 39.5%   
Current liabilities Rs m21,41368,938 31.1%   
Net working cap to sales %48.725.2 192.9%  
Current ratio x1.91.5 127.2%  
Inventory Days Days6474 86.0%  
Debtors Days Days94104 90.9%  
Net fixed assets Rs m50,661104,385 48.5%   
Share capital Rs m3,000830 361.4%   
"Free" reserves Rs m48,808124,886 39.1%   
Net worth Rs m51,808125,716 41.2%   
Long term debt Rs m17,89825,089 71.3%   
Total assets Rs m99,897225,443 44.3%  
Interest coverage x10.618.1 58.3%   
Debt to equity ratio x0.30.2 173.1%  
Sales to assets ratio x0.40.6 65.2%   
Return on assets %5.24.5 113.2%  
Return on equity %8.77.5 116.1%  
Return on capital %9.69.7 99.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05872,623 16.6%   
Fx outflow Rs m7,34818,916 38.8%   
Net fx Rs m4,71053,707 8.8%   
CASH FLOW
From Operations Rs m6,62118,030 36.7%  
From Investments Rs m-6,840-14,883 46.0%  
From Financial Activity Rs m-2,397-4,440 54.0%  
Net Cashflow Rs m-2,612-1,236 211.3%  

Share Holding

Indian Promoters % 40.4 25.5 158.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 5.4 155.6%  
FIIs % 10.7 35.3 30.3%  
ADR/GDR % 0.0 18.5 -  
Free float % 19.9 15.3 130.1%  
Shareholders   109,995 75,885 144.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   AUROBINDO PHARMA  MERCK LTD  GSK PHARMA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare BIOCON LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

DR. REDDYS LAB Plunges by 5%; BSE HEALTHCARE Index Up 0.2% (Market Updates)

Dec 12, 2018 | Updated on Dec 12, 2018

DR. REDDYS LAB share price has plunged by 5% and its current market price is Rs 2,710. The BSE HEALTHCARE is up by 0.2%. The top gainers in the BSE HEALTHCARE Index are GRANULES INDIA (up 3.7%) and SUN PHARMA ADV. RES. (up 2.6%). The top losers is DR. REDDYS LAB (down 5.1%).

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Dec 12, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS